View Item 

Show simple item record

Morphomics predicts response to ipilimumab in patients with stage IV melanoma
dc.contributor.authorSabel, Michael S.en_US
dc.contributor.authorLee, Jayen_US
dc.contributor.authorWang, Anranen_US
dc.contributor.authorLao, Christopheren_US
dc.contributor.authorHolcombe, Svenen_US
dc.contributor.authorWang, Stewarten_US
dc.date.accessioned2015-10-07T20:42:52Z
dc.date.available2016-10-10T14:50:24Zen
dc.date.issued2015-08en_US
dc.identifier.citationSabel, Michael S.; Lee, Jay; Wang, Anran; Lao, Christopher; Holcombe, Sven; Wang, Stewart (2015). "Morphomics predicts response to ipilimumab in patients with stage IV melanoma." Journal of Surgical Oncology 112(4): 333-337.en_US
dc.identifier.issn0022-4790en_US
dc.identifier.issn1096-9098en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/113727
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.othermelanomaen_US
dc.subject.otheripilimumaben_US
dc.subject.otherimmunotherapyen_US
dc.subject.othermorphomicsen_US
dc.titleMorphomics predicts response to ipilimumab in patients with stage IV melanomaen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbsecondlevelSurgery and Anesthesiologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/113727/1/jso24003.pdf
dc.identifier.doi10.1002/jso.24003en_US
dc.identifier.sourceJournal of Surgical Oncologyen_US
dc.identifier.citedreferenceAntoun S, Baracos VE, Birdsell L, et al.: Low body mass index and sarcopenia associatedw tih dose‐limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 2010; 21: 1594 – 1598.en_US
dc.identifier.citedreferenceHodi FS, O'Day SJ, McDermott DF, et al.: Improved survival with ipilimubab in patients with metastatic melanoma. NEJM 2010; 363: 711 – 723.en_US
dc.identifier.citedreferencePrieto PA, Yang JC, Sherry RM, et al.: CTLA‐4 blockade with ipilimumab: Long‐term follow‐up of 177 patients with metastatic melanoma. Clin Cancer Res 2012; 18: 2039 – 2047.en_US
dc.identifier.citedreferenceSabel MS, Lee J, Cai S, et al.: Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol 2011; 18: 3579 – 3585.en_US
dc.identifier.citedreferenceEnglesbe MJ, Patel SP, He K, et al.: Sarcopenia and mortality after liver transplantation. J Am Coll Surg 2010; 211: 271 – 278.en_US
dc.identifier.citedreferenceLee JS, He K, Harbaugh CM, et al.: Frailty, core muscle size, and mortality in patients undergoing open abdominal aortic aneurysm repair. J Vasc Surg 2011; 53: 912 – 917.en_US
dc.identifier.citedreferenceBaumgartner RN, Wayne SJ, Waters DL, et al.: Sarcopenic obesity predicts instrumental activities of daily living disability in the elderly. Obes Res 2004; 12: 1995 – 2004.en_US
dc.identifier.citedreferenceVillareal DT, Banks M, Sinacore DR, et al.: Effect of weight loss and exercise on frailty in obese, older adults. Arch Intern Med 2006; 166: 860 – 866.en_US
dc.identifier.citedreferenceGoodpaster BH, Kelley DE, Thaete FL, et al.: Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol 2000; 89: 104 – 110.en_US
dc.identifier.citedreferenceGoodpaster BH, Thaete FL, Kelley DE: Skeletal muscle composition evaluated with computed tomography. Ann NY Acad Sci 2000; 904: 18 – 24.en_US
dc.identifier.citedreferenceAscierto PA, Kalos M, Schaer DA, et al.: Biomarkers for immunostimulatory monocolonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res 2013; 19: 1009 – 1020.en_US
dc.identifier.citedreferenceKu GY, Yuan J, Page DB, et al.: Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: Lymphocyte count after 2 doses correlates with survival. Cancer 2010; 116: 1767 – 1775.en_US
dc.identifier.citedreferenceBerman D, Wolchock JD, weber J, et al.: Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients with advacned melanoma treated wtih ipilimumab (abstract). J Clin Oncol 2009; 27:abstract 3020.en_US
dc.identifier.citedreferenceYuan J, Adamow M, Ginsberg BA, et al.: Integrated NY‐ESO‐1 antibody and CD8+ T‐cell responses correlate wtih clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci USA 2011; 108: 16723 – 16728.en_US
dc.identifier.citedreferenceFu T, He Q, Sharma P: The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti‐CTLA‐4 therapy. Cancer Res 2011; 16: 3485 – 3494.en_US
dc.identifier.citedreferenceKitano S, Postow MA, Cortez C, et al.: Myeloid derived supressor cell quantity prior to treatment with ipilimumab at 10mg/kg to predict for overall survival in patients with metastatic melanoma (abstract). J Clin Oncol 2012; 30:abstract 2518.en_US
dc.identifier.citedreferencePrado CM, Baracos VE, McCargar LJ, et al.: Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receving capecitabine treatment. Clin Cancer Res 2009; 15: 2920 – 2926.en_US
dc.identifier.citedreferenceAntoun S, Lanoy E, Albiges‐Sauvin L, et al.: Clinical implications of body composition assessment by computed tomography in metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2014; 14: 279 – 288.en_US
dc.identifier.citedreferenceYao X, Li H, Leng SX: Inflammation and immune system alterations in frailty. Clin Geriatr Med 2011; 27: 79 – 87.en_US
dc.identifier.citedreferenceOfford EA, Karagounis LG, Vidal K, et al.: Nutrition and the biology of human aging: bone health & osteoporosis/sarcopenia/immune deficiency. J Nutr Health Aging 2013; 17: 712 – 716.en_US
dc.identifier.citedreferenceMiller AS, Min LC, Diehl KM, et al.: Analytic morphomics coresponds to functional status in older patients. J Surg Res 2014; 192: 19 – 26.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jso24003.pdf
Size:
83.29KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.